Login Register Cart 0
Generic placeholder image

Current Rheumatology Reviews

Editor-in-Chief

ISSN (Print): 1573-3971
ISSN (Online): 1875-6360

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Quality of Life and Disability in Chikungunya Arthritis

Author(s): Jose Kennedy Amaral*, Peter C. Taylor, Michael E. Weinblatt, Ícaro Bandeira and Robert T. Schoen

Volume 20, Issue 1, 2024

Published on: 15 August, 2023

Page: [65 - 71] Pages: 7

DOI: 10.2174/1573397119666230726113647

Price: $65

Abstract

Background: Chikungunya virus infection, transmitted by Aedes mosquito vectors, causes outbreaks of chikungunya fever (CHIKF), throughout the tropical and subtropical world. Following acute infection, many CHIKF patients develop a second phase, chronic and disabling arthritis.

Objective: To evaluate the impact of chikungunya arthritis (CHIKA) on quality of life and disability in a cohort of Brazilian CHIKA patients.

Methods: We conducted a descriptive, non-interventionist, retrospective cross-sectional study analysing data collected from the medical records of chikungunya virus-infected patients treated between June 1, 2022, and June 30, 2022, in the Brazilian rheumatology clinic of one of us (JKA). To assess disability, quality of life, and pain, patients were evaluated using the Health Assessment Questionnaire Disability Index (HAQ-DI), 12-Item Short-Form Health Survey (SF-12), and Visual Analog Scale (VAS) pain.

Results: Forty-two women with a mean (± SD) age of 57.83 (± 13.05) years had CHIKF confirmed by chikungunya-specific serology. The mean (± SD) time between the onset of chikungunya symptoms and the first clinic visit was 55.19 (± 25.88) days. At this visit, the mean (± SD) VAS pain score and DAS28-ESR were 77.26 (± 23.71) and 5.8 (± 1.29), respectively. The mean (± SD) HAQDI score was 1.52 (± 0.67). The mean (± SD) SF-12 PCS-12 was 29.57 (± 8.62) and SF-12 MCS-12 was 38.42 (± 9.85).

Conclusion: CHIKA is often highly disabling. As the mosquito vectors that transmit this illness have spread to every continent except Antarctica, there is a potential for widespread public health impact from CHIKA and the need for more effective, early intervention to prevent CHIKA.

« Previous Next »
Graphical Abstract

[1]
Altman BM. Definitions, concepts, and measures of disability. Ann Epidemiol 2014; 24(1): 2-7.
[http://dx.doi.org/10.1016/j.annepidem.2013.05.018] [PMID: 24268996]
[2]
World Health Organization. International Classification of Functioning, Disability and Health (ICF). Geneva: World Health Organization 2001.
[3]
Megari K. Quality of life in chronic disease patients 2013.
[http://dx.doi.org/10.4081/hpr.2013.932]
[4]
Johnson SR, Glaman DD, Schentag CT, Lee P. Quality of life and functional status in systemic sclerosis compared to other rheumatic diseases. J Rheumatol 2006; 33(6): 1117-22.
[PMID: 16622903]
[5]
Guevara-Pacheco SV, Feican-Alvarado A, Delgado-Pauta J, Lliguisaca-Segarra A, Pelaez-Ballestas I. Prevalence of disability in patients with musculoskeletal pain and rheumatic diseases in a Population From Cuenca, Ecuador. J Clin Rheumatol 2017; 23(6): 324-9.
[http://dx.doi.org/10.1097/RHU.0000000000000571] [PMID: 28816770]
[6]
Rezvani A, Bodur H, Ataman Ş, et al. Correlations among enthesitis, clinical, radiographic and quality of life parameters in patients with ankylosing spondylitis. Mod Rheumatol 2014; 24(4): 651-6.
[http://dx.doi.org/10.3109/14397595.2013.850182] [PMID: 24252034]
[7]
Park EH, Strand V, Oh YJ, Song YW, Lee EB. Health-related quality of life in systemic sclerosis compared with other rheumatic diseases: A cross-sectional study. Arthritis Res Ther 2019; 21(1): 61.
[http://dx.doi.org/10.1186/s13075-019-1842-x]
[8]
Amaral JK, Bilsborrow JB, Schoen RT. Brief report: The disability of chronic chikungunya arthritis. Clin Rheumatol 2019; 38(7): 2011-4.
[http://dx.doi.org/10.1007/s10067-019-04529-x] [PMID: 30963336]
[9]
Bettis AA, L’Azou Jackson M, Yoon IK, et al. The global epidemiology of chikungunya from 1999 to 2020: A systematic literature review to inform the development and introduction of vaccines. PLoS Negl Trop Dis 2022; 16(1): e0010069.
[http://dx.doi.org/10.1371/journal.pntd.0010069]
[10]
Rodríguez-Morales AJ, Cardona-Ospina JA, Fernanda Urbano-Garzón S, Sebastian Hurtado-Zapata J. Prevalence of post chikungunya infection chronic inflammatory arthritis: A systematic review and meta-analysis. Arthritis Care Res 2016; 68(12): 1849-58.
[http://dx.doi.org/10.1002/acr.22900] [PMID: 27015439]
[11]
Wahid B, Ali A, Rafique S, Idrees M. Global expansion of chikungunya virus: Mapping the 64-year history. Int J Infect Dis 2017; 58: 69-76.
[http://dx.doi.org/10.1016/j.ijid.2017.03.006] [PMID: 28288924]
[12]
van Aalst M, Nelen CM, Goorhuis A, Stijnis C, Grobusch MP. Long-term sequelae of chikungunya virus disease: A systematic review. Travel Med Infect Dis 2017; 15: 8-22.
[http://dx.doi.org/10.1016/j.tmaid.2017.01.004] [PMID: 28163198]
[13]
Doran C, Elsinga J, Fokkema A, et al. Long-term Chikungunya sequelae and quality of life 2.5 years post-acute disease in a prospective cohort in Curaçao. PLoS Negl Trop Dis 2022; 16(3): e0010142.
[http://dx.doi.org/10.1371/journal.pntd.0010142]
[14]
Bruce B, Fries JF. The Stanford Health Assessment Questionnaire: A review of its history, issues, progress, and documentation. J Rheumatol 2003; 30(1): 167-78.
[PMID: 12508408]
[15]
Hjermstad MJ, Fayers PM, Haugen DF, et al. Studies comparing numerical rating scales, verbal rating scales, and visual analogue scales for assessment of pain intensity in adults: A systematic literature review. J Pain Symptom Manage 2011; 41(6): 1073-93.
[http://dx.doi.org/10.1016/j.jpainsymman.2010.08.016] [PMID: 21621130]
[16]
Damásio BF, Andrade TF, Koller SH. Psychometric properties of the Brazilian 12-item Short-Form Health Survey Version 2 (SF 12v2). Paidéia 2015; 25(60): 29-37.
[17]
Wells G, Becker J-C, Teng J, et al. Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Ann Rheum Dis 2009; 68(6): 954-60.
[http://dx.doi.org/10.1136/ard.2007.084459] [PMID: 18490431]
[18]
Kirkwood BR, Sterne JAC. Essential Medical Statistics. (2nd ed.). Oxford, United Kingdom: Blackwell 2003; pp. 58-79.
[19]
Watson H, Tritsch SR, Encinales L, et al. Stiffness, pain, and joint counts in chronic chikungunya disease: relevance to disability and quality of life. Clin Rheumatol 2020; 39(5): 1679-86.
[http://dx.doi.org/10.1007/s10067-019-04919-1] [PMID: 31916107]
[20]
de Oliveira BFA, Carvalho PRC, de Souza Holanda AS, et al. Pilates method in the treatment of patients with Chikungunya fever: A randomized controlled trial. Clin Rehabil 2019; 33(10): 1614-24.
[http://dx.doi.org/10.1177/0269215519856675] [PMID: 31230466]
[21]
Abella J, Rojas Á, Rojas C, et al. Clinical and immunological features of post-chikungunya virus chronic arthritis and its effect on functional ability and quality of life in a cohort of Colombian patients. Revista Colombiana de Reumatología 2019; 26(4): 253-9.
[http://dx.doi.org/10.1016/j.rcreue.2019.12.001]
[22]
Pandya S. Methotrexate and hydroxychloroquine combination therapy in chronic chikungunya arthritis: A 16 week study. Indian J Rheumatol 2008; 3(3): 93-7.
[http://dx.doi.org/10.1016/S0973-3698(10)60125-2]
[23]
Blettery M, Brunier L, Polomat K, et al. Brief report: Management of chronic post-chikungunya rheumatic disease: the martinican experience. Arthritis Rheumatol 2016; 68(11): 2817-24.
[http://dx.doi.org/10.1002/art.39775] [PMID: 27273928]
[24]
Ravindran V, Alias G. Efficacy of combination DMARD therapy vs. hydroxychloroquine monotherapy in chronic persistent chikungunya arthritis: A 24-week randomized controlled open label study. Clin Rheumatol 2017; 36(6): 1335-40.
[http://dx.doi.org/10.1007/s10067-016-3429-0] [PMID: 27699657]
[25]
Bouquillard E, Fianu A, Bangil M, et al. Rheumatic manifestations associated with Chikungunya virus infection: A study of 307 patients with 32-month follow-up (RHUMATOCHIK study). Joint Bone Spine 2018; 85(2): 207-10.
[http://dx.doi.org/10.1016/j.jbspin.2017.01.014] [PMID: 28238882]
[26]
Soumahoro MK, Gérardin P, Boëlle PY, et al. Impact of Chikungunya virus infection on health status and quality of life: A retrospective cohort study. PLoS One 2009; 4(11): e7800.
[http://dx.doi.org/10.1371/journal.pone.0007800]
[27]
Simon F, Bossy R, Federico D, et al. Determinants of health-related quality of life in chronic Chikungunya Disease in Guadeloupe. Pathogens 2022; 11(9): 989.
[http://dx.doi.org/10.3390/pathogens11090989]
[28]
Dantas A, Luna M, Santos P. SAT0562 Chikungunya fever in patients with prior rheumatic diseases: Is it more severe? Ann Rheum Dis 2017; 76: 989.
[http://dx.doi.org/10.1136/annrheumdis-2017-eular.6560]
[29]
Suhrbier A. Rheumatic manifestations of chikungunya: Emerging concepts and interventions. Nat Rev Rheumatol 2019; 15(10): 597-611.
[http://dx.doi.org/10.1038/s41584-019-0276-9] [PMID: 31481759]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy